The evaluation and management of urolithiasis in the ED: A review of the literature.
Michael Gottlieb, Brit Long, Alex Koyfman
https://pubmed.ncbi.nlm.nih.gov/29321112/Actively Recruiting
Led by Community Medical Center, Toms River, NJ · Updated on 2025-07-17
92
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the use of Virtual Reality VR and Augmented Reality AR calming applications as an addition to standard drug treatment for patients experiencing renal colic in the Emergency Department. It compares standard pharmacologic pain management alone to pharmacologic management combined with a calming VRAR app using a commercial headset. The study focuses on patients with a history of kidney stones and moderate to severe pain. Participants will be randomly assigned to one of two groups one receiving standard pharmacologic care at the providers discretion, and the other receiving the same pharmacologic care plus the use of a calming ARVR app via a commercial headset. The app is used as an adjunct to pain medication, intended to help reduce pain during the emergency visit. During the study, participants will be monitored for pain levels at 30 and 60 minutes, heart rate and blood pressure at 30 and 60 minutes, use of additional pain medication within 4 hours, and any rescue interventions within 24 hours. Participants must comply with the VR treatment by keeping the headset on and understanding the instructions. The overall aim is to see if the addition of the VRAR calming app affects pain and vital signs during renal colic treatment.
CONDITIONS
The Use of AR / VR in Patients Presenting to the ED With Renal Colic
G
Greg Neyman, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Community Medical Center, Toms River, NJ
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AR/VR adjunct plus standard pharmacologic care | Standard pharmacologic care (NSAIDs/opioids) | Usual NSAID‑based pain management |
|---|---|---|---|
| What it is | Use of a commercial AR/VR headset with calming application in addition to usual pharmacologic pain management for emergency department patients with renal colic. | Standard pharmacologic management (e.g., NSAIDs and opioids) without any AR/VR adjunct. | NSAID‑based analgesia is the usual first‑line pain management in emergency settings for renal colic. |
| Role in trial | Investigational adjunct evaluated for additional pain relief. | Active comparator arm receiving standard pain‑relieving medications. | Represents current emergency department analgesic practice for renal colic. |
| Primary use | Adjunctive pain relief method to complement standard medications. | Standard pharmacologic relief of renal colic pain. | First‑line pharmacologic treatment often relies on NSAIDs in clinical practice. |
| How it is given or performed | Participants receive usual pharmacologic treatment and wear an AR/VR headset with calming app during ED care. | Participants receive standard pharmacologic analgesics without AR/VR. | NSAIDs administered according to emergency department protocols, typically intravenously. |
| Evidence status | Efficacy in renal colic is under investigation; benefit over standard care not yet established. | Proven analgesic effect for acute renal colic based on established ED use. | NSAIDs shown to reduce pain more than opioids and reduce need for rescue analgesia. |
| Important risks | Potential for motion sickness, anxiety, or discomfort from AR/VR use. | Known risks include NSAID‑associated gastrointestinal or renal effects and opioid‑related sedation or nausea. | NSAIDs have lower risk of vomiting compared to opioids, but still carry general NSAID risks. |
| Important limitations | Study results not yet available; unknown whether AR/VR adds clinically meaningful analgesic benefit. | NSAIDs may be contraindicated in patients with renal impairment or other comorbidities. | Opioids still used when NSAIDs contraindicated or insufficient; potential side effects limit NSAID use in some patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 minutes
Participants receive either standard pharmacologic pain management alone or pharmacologic management plus use of an adjunct Virtual/Augmented Reality calming application using a commercial AR/VR headset while in the emergency department for renal colic.
1 treatment visit (in-person)
Duration - Up to 24 hours
Participants are monitored for additional pain relief needs and safety for up to 24 hours after treatment.
Follow-up assessments up to 24 hours post-treatment (may be remote or in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Michael Gottlieb, Brit Long, Alex Koyfman
https://pubmed.ncbi.nlm.nih.gov/29321112/Elaine M Worcester, Fredric L Coe
https://pubmed.ncbi.nlm.nih.gov/18486720/Ali Pourmand, Steven Davis, Alex Marchak...
https://pubmed.ncbi.nlm.nih.gov/29904806/Anna Holdgate, Tamara Pollock
https://pubmed.ncbi.nlm.nih.gov/15178585/Laurens Weynants, Brecht Chys, Pieter D'hulst...
https://pubmed.ncbi.nlm.nih.gov/36680576/Brian Mallari, Emily K Spaeth, Henry Goh...
https://pubmed.ncbi.nlm.nih.gov/31308733/Community Medical Center, Toms River, NJ
Lead Sponsor